5'-Adenylic acid Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

Several clinical trials are currently evaluating interventions across diverse conditions, including child sexual abuse, overweight and obesity, ischemic stroke associated with CYP2C19 polymorphism, and amputation. Reflecting exploratory, behavioral, or diagnostic designs, these protocols feature unspecified or non-applicable trial phases. Managed by various academic, healthcare, and commercial sponsors, participant recruitment statuses range from not yet recruiting to actively recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06126926	Not yet recruiting	Child Sexual Abuse	University of Minnesota	2024-06-15	Not Applicable
NCT04433273	Not yet recruiting	Overweight and Obesity	Neurovalens Ltd.\|Compliance Solutions Ltd.\|RD Gardi Medical College	2024-05	Not Applicable
NCT06292117	Recruiting	Ischemic Stroke\|CYP2C19 Polymorphism	University of Virginia\|American Heart Association	2024-04-16	--
NCT06406491	Recruiting	Amputation	Median\|Johannes Gutenberg University Mainz	2024-04-23	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 5'-Adenylic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

5'-Adenylic acid directly binds to the regulatory gamma subunits of AMP-activated protein kinase (AMPK), inducing conformational changes that promote kinase phosphorylation and downstream metabolic signaling cascades. This activation suppresses energy-consuming anabolic biochemical pathways while stimulating ATP-generating catabolic processes, resulting in enhanced cellular energy homeostasis and metabolic regulation relevant to clinical conditions such as overweight and obesity.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).